{"entity":{"id":"nct06833073","kind":"trial","name":"A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)","aka":["INTerpath-011"],"tldr":"A phase 2 trial of Intismeran autogene in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, now recruiting.","summary":"A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) is a phase 2 interventional study registered as NCT06833073 by Merck Sharp & Dohme LLC, with 308 participants planned, started 2025-03-11 and due to reach its primary completion in 2031-09-03. Interventions recorded: Intismeran autogene and BCG.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06833073","url":"https://clinicaltrials.gov/study/NCT06833073"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial","non-muscle-invasive-bladder-cancer"],"sections":[],"technologies":["neoantigen-mrna-vaccine"],"targets":[],"drugs":["intismeran-autogene"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06833073","phase":"2","setting":"A Phase 2 Open-label Randomized Study of V940 in Combination With BCG Versus BCG Monotherapy in Participants With High-risk Non-muscle Invasive Bladder Cancer (INTerpath-011)","sponsor":"Merck Sharp & Dohme LLC","participation":[{"nct":"NCT06833073","source":"https://clinicaltrials.gov/study/NCT06833073","fetchedAt":"2026-10-07T16:55:06.589Z","studySha256":"7b3f1ab457a27e3ae360e306e746f521df8d0f32f5a304de7e838133c8afa7fb","overallStatus":"RECRUITING","lastUpdatePosted":"2026-10-01","leadSponsor":"Merck Sharp & Dohme LLC","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":308,"enrolmentType":"ESTIMATED","siteCount":89,"recruitingSiteCount":84,"countries":["Argentina","Australia","Brazil","Canada","Chile","Colombia","Denmark","France","Germany","Greece","Hungary","Italy","Netherlands","Peru","Poland","Spain","Thailand","United Kingdom","United States"]}],"started":"2025-03-11","startedType":"actual","enrolled":308,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06833073/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"non-muscle-invasive-bladder-cancer","kind":"cancer","name":"Non-muscle-invasive bladder cancer","route":"/cancers/non-muscle-invasive-bladder-cancer/"}],"technology":[{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"drug":[{"id":"intismeran-autogene","kind":"drug","name":"Intismeran autogene","route":"/drugs/intismeran-autogene/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}]}}